Recent Updates
Recently added Catalysts

Exparel Injectable Product

Phase 3

Coronary Artery Disease | Small molecule | Cardiovascular |Pacira BioSciences, Inc.|Last Updated: Sep 5, 2021

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment60
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03270514Comparison of Sternal Wound Infiltration With Liposomal Bupivacaine v. Bupivacaine HydrochloridePHASE3 COMPLETED 60Nov 15, 2018Feb 25, 2020Sep 5, 20211 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Post-operative Pain Intensity
NRS scores will be evaluated every 4 hours until 24 hours post-operatively, every 8 hours until 48 hours post-operatively, and every 12 hours for 72 hours post-operatively

Postoperative pain scores evaluated by numeric rating scale or (NRS) where 0- no pain and 10- worst pain, at rest and at movement

Total Narcotic Consumption
0-72 hours post-operative period

All narcotics administered in the first 0-8, 8-24, 24-48, and 48-72 hours and the total narcotics administered in the 0-72 hours postoperative period(PCA narcotics, nurse-administered IV narcotics, and oral narcotics). All narcotics will be converted to total IV morphine equivalent for comparison between two groups.

Secondary Endpoints
Time to Extubation
From the end of surgery until the patient is extubated up to 72 hours post-operatively
Patient Time to Mobilization
From time of end of surgery to time of mobilization up to 72 hours or discharge, *assessed up to 120 hours*
Patient Time to Out of Bed to Chair
From time of end of surgery to time of mobilization up to 72 hours post-operatively
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Exparel Injectable ProductEXPERIMENTALLiposomal Bupivacaine (Exparel) Injection administered approximately 20 cc per inch of sternotomy wound. Half of subjects enrolled will be randomized to the liposomal bupivacaine (Exparel) group (\~30).
Bupivacaine HydrochlorideACTIVE_COMPARATORBupivacaine Injection administered approximately 20 cc per inch of sternotomy wound. Half of subjects enrolled will be randomized to the bupivacaine group (\~30).
Interventions
NameTypeDescription
Exparel Injectable ProductDRUGLiposomal bupivacaine 20 cc (226 mg) + Bupivacaine Hydrochloride 0.25% 40 cc (100 mg) + made up to calculated volume with normal saline solution based on the length of the incision and number of chest tubes (20 cc per tube + 20cc per inch of incision)
Bupivacaine HydrochlorideDRUGBupivacaine 0.25% 2 mg/kg not to exceed 150 mg - made up to made up to calculated volume with normal saline solution based on the length of the incision and number of chest tubes (20 cc per tube + 20cc per inch of incision)
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Open cardiac surgery through sternotomy approach (eg. coronary artery bypass graft, valvular heart procedures, as well as other open cardiac procedures along with coronary artery bypass) * Surgery with the use of cardiopulmonary bypass Exclusion Criteria: * Minimally invasiv...

Countries:United States
Unlock Eligibility Criteria